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CD4 T cells with cytotoxic function were once thought to be an artifact due to long-
term in  vitro cultures but have in more recent years become accepted and reported 
in the literature in response to a number of viral infections. In this review, we focus on 
cytotoxic CD4 T cells in the context of human viral infections and in some infections that 
affect mice and non-human primates. We examine the effector mechanisms used by 
cytotoxic CD4 cells, the phenotypes that describe this population, and the transcription 
factors and pathways that lead to their induction following infection. We further consider 
the cells that are the predominant targets of this effector subset and describe the viral 
infections in which CD4 cytotoxic T lymphocytes have been shown to play a protective 
or pathologic role. Cytotoxic CD4 T cells are detected in the circulation at much higher 
levels than previously realized and are now recognized to have an important role in the 
immune response to viral infections.
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iNTRODUCTiON
It is well established that CD4 T cells play a significant, often central, role in the immune response 
to viral infections. CD4 T cells provide both “help” to enable B cells to generate effective neutral-
izing antibodies through affinity maturation and antibody class switching, as well as promoting the 
development and maintenance of cytotoxic virus-specific CD8 T cell responses. CD4 T cells have 
an ability to be functional memory cells and can themselves have a direct antiviral effect, although 
this is a lesser known role. Between 1977 and 2001, CD4 T cells with cytotoxic characteristics were 
described sporadically in the literature.
Initial reports of CD4 T cells with cytotoxic characteristics from cultured CD4 T cell lines and 
clones (1–5) were met with doubt as to whether these CD4 T cells were in fact true cytotoxic T lym-
phocytes (CTL), or an anomaly owing to long-term in vitro cultures (6). Only one report described 
human Leu3a+ CTL in PBMC, prior to the introduction of the CD4 nomenclature (7). The Leu3a 
antibody is CD4 specific, so that this report described Cytomegalovirus (CMV)-specific “helper” 
cells with an ex vivo CTL function, prior to the introduction of the CD nomenclature. From 2001, 
the ability of human CD4 to function as CTL ex vivo began to be more widely reported (8–13). 
Further, there is increasing evidence that cytolytic CD4 T cells (CD4 CTL) are detected following 
vaccinations, including against smallpox (14, 15), poliovirus (16), and in response to the vaccines 
(ALVAC/AIDSVAX) given in the RV144 HIV vaccine study (17).
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Herein, we review the characteristics of CD4 CTL across a 
range of human viral infections including human immunodefi-
ciency virus type 1 (HIV-1) (9–11, 18–20), CMV (8, 10, 12, 21, 
22), Epstein–Barr virus (EBV) (23–25), influenza (26, 27), viral 
hepatitis (28), hantavirus (29), dengue (30–33), and parvovirus 
B19 (34). CD4 CTL may also be involved more broadly in the 
regulation of immune responses, through regulatory T cell (Treg) 
function (to be discussed later) and may also be involved in other 
non-viral infections and anti-tumor responses. Clearly, these cells 
represent an additional mechanism by which CD4 T cells con-
tribute generally to human immunity, and below we concentrate 
on antiviral immunity.
CYTOTOXiC eFFeCTOR MeCHANiSMS
CD4 Cytotoxicity via Fas Ligand
CD4 CTL utilize two fundamental cytotoxic effector mechanisms 
used also by CD8 CTL and natural killer (NK) cells. The first 
is the Fas/Fas ligand-mediated pathway, which involves binding 
of the cell surface Fas ligand (FasL; CD95L; CD178) expressed 
on the effector cells binding to its cognate receptor Fas (CD95) 
expressed on the target cells. Trimerization of Fas on the target cell 
leads to recruitment of the intracellular FADD/caspase 8/c-FLIP 
death-inducing signaling complex, and finally to caspase 3-medi-
ated apoptotic cell death (35–37).
CD4 Cytotoxicity via Perforin and 
Granzymes
The second major mechanism of cytotoxicity is the directed 
exocytosis of specialized granules into target cells to induce 
apoptosis [reviewed in Ref. (38)]. Cytotoxic granules were origi-
nally characterized in CD8 CTL and NK cells as large vesicles, 
which in turn contain numerous smaller internal vesicles and an 
electron dense core (39). Cytotoxic granules undergo exocytosis 
after specific T cell receptor (TCR) signaling; a key regulator 
of this process is Rab27a. Genetic defects in Rab27a result in 
Griscelli syndrome type 2 [reviewed in Ref. (40)] an autosomal 
recessive disorder of pigmentation and severe immune deficiency 
(41). The pore-forming protein perforin is the best-described 
cytotoxic molecule in these granules (42, 43); it enables direct 
transfer of cytotoxic molecules such as granzymes and granuly-
sin into target cells. There are five known granzymes or serine 
proteases in humans (A, B, H, K, and M) with various substrate 
specificities [reviewed in Ref. (44–47)]. Granzyme (Gzm) A and 
GzmB are the most extensively studied and are the most abun-
dant in cytotoxic granules (48, 49), while the other granzymes H, 
K, and M are less well understood. GzmA and GzmK genes are 
located on chromosome 5 in humans and on chromosome 13 in 
mice [reviewed in Ref. (50)], and while both have tryptase-like 
activity, there is only partial overlap of substrates in vivo (51). In 
contrast, GzmB and GzmH (GzmC in mice) are chymases, with 
genes located on chromosome 14 in humans and mice [reviewed 
in Ref. (44)].
Given the well-defined nature of CD8 CTL in comparison 
to CD4 CTL, comparisons of the cytolytic machinery of both 
T cell subsets can further our understanding of the relative 
impact of CD4 cytolytic activity in infection. In a recent murine 
study of lymphocytic choriomeningitis virus, Hildemann 
et al. used an in vivo CTL assay to demonstrate that CD4 CTL 
were readily generated and had comparable CTL activity to 
CD8 CTL when factors such as effector to target ratios were 
adjusted (52). A difference they noted between CD4 and CD8 
CTL killing was the slightly delayed killing kinetics of the CD4 
CTL (52). Another comparison showed that CD8 CTL stored 
more intracellular GzmB than CD4 T cells; however, secretion 
of GzmB was equivalent between both T cell subsets (although 
CD8 T cells secreted more perforin than CD4) (53). In our 
recent study of activated CD4 and CD8 T cells responding to 
primary HIV-1 infection and vaccination with vaccinia virus, 
we confirmed that CD8 T cells express significantly higher 
levels of perforin and T cell intracellular antigen, TIA-1 [gene 
name nkg7, also known as granule membrane protein, GMP-17 
(54)] compared to CD4 T cells (15). Despite these apparent dif-
ferences in the carriage of cytolytic machinery, it would appear 
from the above studies that the antiviral activity of CD4 and 
CD8 CTL is similar.
PHeNOTYPe OF CD4 CTL iN HeALTHY 
ADULTS
Perforin-expressing CD4 T cells identified ex vivo in peripheral 
blood from healthy humans have a distinct cell surface phe-
notype. These cells in healthy adults are typically CD45RO+, 
highly express the integrins CD11a and CD11b, and do not 
express the costimulatory receptors CD27 or CD28, or the 
chemokine receptor CCR7 (9). CD4 CTL detected in healthy 
human blood are not activated and are not undergoing 
proliferation, as they are CD38low, CD69neg, Ki67neg, and 
Bcl-2high (9). Also, CD4 CTL are distinct from NK T cells as 
they do not express CD16, CD56, or CD161 (9). CD57 expres-
sion, a marker of terminal differentiation (55), appears to be 
upregulated on CD4 CTL (56).
Another marker associated with CD4 CTL is Fc receptor-like 
6 (FCRL6); Schreeder et al. found that FCRL6+ CD4 T cells also 
expressed perforin, CD57, and NKG2D (57). NKG2D, originally 
identified on NK cells, is a killer lectin-like receptor. Following 
ligation, NKG2D initiates an intracellular cascade leading to 
perforin exocytosis and consequently cytotoxicity. Expression of 
NKG2D on CD4 T cells has been suggested to occur following 
repeated exposures to antigen and is significantly increased in 
elderly (mean age: 84.3  years) compared to young (mean age: 
39  years) adults (58). In contrast to CD28+ NKG2D+ CD4 T 
cells, their CD28null counterparts express perforin and GzmB 
and have a more differentiated phenotype (58). Hence, the overall 
phenotype of CD4 CTL in healthy adults indicate that these cells 
are at an advanced stage of cellular differentiation, consistent 
with the suggestion that these cells are generated in the presence 
of chronic antigen exposure (56, 59, 60). However, we and oth-
ers have shown that CD4 CTL are also detected in the primary 
response to acute viral infections, which will be discussed later 
in this review. Table  1 provides a summary of the CD4 CTL 
phenotypes described in healthy adults, non-human primates, 
and mice in response to various viral infections.
TABLe 1 | Summary of known CD4 cytotoxic T lymphocyte (CTL) phenotype and mechanism of cytolysis in human, non-human primate (NHP), and 
murine models.
Model Phenotype Conditions Reference
Healthy adults Cell surface CD11a/b+, CD27−, CD28− CD45RO+, CCR7− Appay et al. (9)
Activation CD38lo, CD69−, Bcl2++, Ki67− Appay (56)
Differentiation CD57+, perforin, GzmB Appay et al. (9) and Appay (56)
Effector CD57+, FRCL6+, NKG2D+, perforin+ Schreeder et al. (57)
Senescence NKG2D+ Alonso-Arias et al. (58)
Regulatory T cells 
(Tregs)
Human GzmB+ In vitro (αCD3, αCD28, IL-2) Efimova and Kelley (106)
Tregs Murine GzmA+, GzmB+, perforin+ In vitro phenotype (effector 
CD4 T-cell+ IL-2++)
Czystowska et al. (111)
Infection/pathogen
Human 
immunodeficiency 
virus type 1 (HIV-1)
Human GzmA+, perforin+, TIA-1/GMP-17+ Appay et al. (9)
Acute HIV-1 Human CD38+++, CD57−, Bcl2lo, IFN-γ, Ki67+, TIA-1+ Zaunders et al. (117)
Simian 
immunodeficiency 
virus
NHP CD28+, CD45RA−, CD95+, CCR7−, GrzmB+ von Gegerfelt et al. (113)
Cytomegalovirus 
(CMV)
Human CD28−, CD27−, GzmB+, perforin+ Therapy cessation van Leeuwen et al. (12)
CD27−, CD28−, perforin+ Latent CMV Appay et al. (9)
CD244+, CCR5+, GzmA+ IFN-γ+, TIA-1+ Latent CMV Zaunders et al. (10) and Zaunders 
et al. (117)
CD107a, GzmA+ GzmB+, IFN-γ+, MIP-1β+, perforin+, 
TNF+
Latent CMV Casazza et al. (21)
CX3CR1+, Gransulysin+, GzmA/B/H+, IFN-γ+, 
perforin+, TNF+
In vitro phenotype Pachnio et al. (130)
CD28−, CX3CR1+, NKG2D+, perforin+ Posttransplant Shabir et al. (132)
Acute CMV Human CD27−, CD28+, IFN-γ+, GrzmB+, TNF+ (acute) Gamadia et al. (128)
Epstein–Barr virus Human Eomes+Tbet+ In vitro phenotype (CD137) Akhmetzyanova et al. (151)
Influenza Human Perforin+, GzmB+ Vaccine phenotype (BMDC, 
αCD3, IFN-γ, IL-2), in vitro 
phenotype
Zhou and McElhaney (126)
Influenza Mouse GzmB+ (CpG stimulus) Vogel and Brown (164)
GzmB+ (PR8) Brown et al. (72)
Perforin+, GzmB+ In vitro phenotype and tissue 
resident
Hua et al. (64)
Vaccinia Human CD4+ CD8− Leu11−
 
IFN-γ+ TIA-1+ CD57−
GrzmA, GrzmK, KLRB1/CD161, Rab27a, granulysin, 
TIA-1, perforin
 
 
Vaccine phenotype
Microarray analysis
Littaua et al. (159)
Demkowicz et al. (160)
Zaunders et al. (14)
Munier et al. (15)
Ectromelia Mouse GzmB+ Fang et al. (157)
Hepatitis Human Perforin+ Hepatitis B virus Aslan et al. (28)
Perforin+ Hepatitis C virus Aslan et al. (28)
Perforin++ Hepatitis D virus Aslan et al. (28)
Dengue Human Perforin+ Antigen-presenting cell targets Gagnon et al. (77)
Fas/FasL HepG2 cells Weiskopf et al. (155)
CD45RA+ CCR6−, CCR7−, CCR4−, CXCR3−, CD8a+, 
CD107a+, Gzm+, Eomes+, CX3CR1+
Parvovirus Human CD57+, GzmB+, perforin+, IL-17+ In vitro phenotype Kumar et al. (34)
Hantavirus Human GzmB+, perforin+, CD107a± Ma et al. (29)
Human 
papillomavirus
Human CD28− NKG2D+ (CD107a and CD161 negatively 
correlated with frequency)
Garcia-Chagollan et al. (102)
Parentheses () indicate the conditions applied to each model, which has been linked to phenotype.
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FiGURe 1 | Mechanisms of CD4 cytotoxic T lymphocyte (CTL) 
generation. (1) Peptide stimulation in conjunction with IL-2 signaling induces 
CD4 CTL activity in vitro. (2) Interferon signaling or other inflammatory 
cytokine signals can synergize with or compensate for low IL-2 signaling to 
promote acquisition of cytolytic function. (3) The inclusion of a CxxC motif in 
flanking residues of the peptide antigen is thought to improve the strength of 
the immunological synapse and promote cytotoxicity. (4) Class I-restricted T 
cell-associated molecule-mediated intracellular signaling promotes Eomes 
expression and the acquisition of cytolytic activity.
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MeCHANiSMS ReGULATiNG CD4 CTL 
DeveLOPMeNT
Transcription Factors Conferring 
Cytotoxicity
It remains a matter of debate whether CD4 CTL represent a 
novel CD4 T cell lineage, or simply a subset of cells that have 
acquired cytotoxic function in addition to conventional T helper 
characteristics. Detailed studies have established the role of a 
series of transcription factors (TFs) in regulating T helper fate 
(61), leading to the question of whether specific TFs are also 
required for CD4 CTL development. The T-box family TFs T-bet 
and Eomesodermin (Eomes) have been known for some time as 
master regulators of cytotoxicity in CD8 CTL (62, 63); recently, 
studies have confirmed a role for both molecules in regulating 
CD4 T cell cytotoxicity as well. While T-bet expression is required 
for the induction of the CD4 Th1 lineage and IFN-γ production, 
it can also bind to the promoters of GzmB and Prf1 in both 
CD4 and CD8 T cells (64, 65). During influenza infection, the 
binding of T-bet to cytotoxic gene promoters in CD4 T cells is 
regulated by Blimp-1 expression via a mechanism involving IL-2, 
type I interferons, and STAT2 signaling (64). T-bet- or Blimp-
1-deficient T cells display impaired GzmB expression in  vivo, 
confirming the role of these TFs in CD4 CTL activity. T-bet is 
not, however, the only TF involved in conferring cytotoxicity on 
CD4 T cells. Qui et al. were the first to demonstrate a requirement 
for Eomes in GzmB expression by CD4 T cells (66), although 
they did not assess its contribution to other mechanisms of CD4 
CTL killing. To specifically dissect how expression of Eomes 
contributes to the generation of CD4 CTL, Eshima et al. trans-
fected two murine CD4 T cell lines with a single copy of Eomes 
and assessed the expression of both perforin/granzyme and Fas/
FasL cytotoxic pathways (67). Transfection of Eomes resulted in 
the acquisition of IFN-γ expression, upregulation of FasL upon 
antigenic stimulation, and expression of perforin/granzyme that 
lead to acquisition of cytotoxic activity. Interestingly, expression 
of Eomes induced cytotoxicity more efficiently than transfection 
with the perforin gene, suggesting that Eomes confers cytotoxicity 
on T cells through additional mechanisms beyond the induction 
of perforin expression.
A critical clue as to how Eomes is induced in CD4 CTL 
came from a new study by Takeuchi et al., who identified class 
I-restricted T cell-associated molecule (CRTAM) as a determinant 
of a putative CD4 CTL lineage in humans and mice (68). CRTAM, 
a surface membrane protein that binds the ligand cell adhesion 
molecule 1, is expressed on a portion of memory and naïve CD4 
T cells following activation. CRTAM-expressing CD4 cells are 
capable of IFN-γ production under Th0 polarizing conditions, 
express elevated levels of Eomes and GzmB, and can differentiate 
into CD4 CTL in vitro (Figure 1). Intracellular signaling through 
the cytoplasmic domain of CRTAM is required for the expression 
of Eomes, IFN-γ, and GzmB/perforin in CRTAM+ cells, placing 
CRTAM upstream of Eomes in a signaling pathway that regulates 
CD4 CTL development. Interestingly, CRTAM+ CD4 cells are 
found preferentially in the lung and intestinal lamina propria, the 
same tissues in which CD4 CTL are efficiently generated during 
viral infections in murine models (discussed further below). The 
authors confirmed that viral infection increases the frequency 
of CRTAM+ cells in the lung and that CRTAM knock-out mice 
exhibit decreased CD4 CTL activity during infection. Overall, 
these results suggest that CRTAM+ CD4 T cells represent the pre-
cursor of CD4 CTL and identify CRTAM as both a useful marker 
for identifying potential CD4 CTL and a potential therapeutic 
target to modulate CD4 CTL activity in vivo.
While the majority of the studies described above focused on 
CD4 CTL isolated from peripheral blood or the lungs, Mucida 
et al. recently described the presence of CD4 CTL in the murine 
gut (69). In healthy mice, they identified a CD4 T cell population 
that did not express the master Th regulator ThPOK (or cKrox, 
encoded by Zbtb7b). ThPOK is responsible for inducing Th fate 
and repressing the expression of the CD8 CTL regulator Runx3 
in thymocytes. As such, all CD4 T cells isolated from the spleen 
and lymph nodes of ThoPOK-reporter mice expressed ThPOK; 
in contrast, many CD4+ intraepithelial lymphocytes (IELs) were 
ThPOK− and CD8a+. These ThPOK− CD4 T cells phenotypically 
resembled CD8 CTL, including the expression of GzmB, CD107a, 
and LAMP-1, and were capable of killing in vitro. Interestingly, 
CRTAM expression was also detected on the ThPOK−CD8a+ 
CD4 CTL, providing additional evidence to support CRTAM as 
a marker of CD4 CTL in multiple tissues. The authors confirmed 
that the IEL CD4 CTL lost ThPOK expression post-thymically, 
differentiated into CD4 CTL in the context of chronic antigen 
exposure, and exhibited killing following antigen and IL-15 
stimulation. Subsequent studies demonstrated that T-bet and 
Runx3 expression are responsible for driving the loss of ThPOK 
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in IELs (70, 71). Overall, these data provide compelling evidence 
of CD4 T cell plasticity, and the ability of lineage-committed T 
helper cells to be re-directed toward cytotoxicity.
Cytokine Microenvironment and Antigen 
Stimulation
The identification of CD4 CTL both in healthy humans and 
directly ex vivo following viral infection raises the question of 
how these cells are generated in vivo. Although this issue has been 
challenging to address, in vitro studies and insights from in vivo 
mouse experiments have provided clues to mechanisms that are 
likely also relevant in humans in  vivo (Figure  1). Importantly, 
studies of influenza infection in mice have demonstrated that the 
generation of CD4 CTL does not necessarily require prolonged, 
chronic antigen stimulation, but can instead occur during acute 
infection (72, 73). Overall, it appears that the combination of a 
cytokine-mediated inflammatory signal and antigen presentation 
is required for CD4 T cells to acquire cytotoxicity (69, 74).
Although CD4 cytolytic activity is commonly observed in Th1 
cells (75–77), CD4 CTL can be generated in vitro prior to full Th 
polarization and differentiation and do not require IFN-γ (78). 
IL-2, however, appears to be critical in the generation of CD4 
CTL in both mice (64, 66, 79) and in ex vivo human peripheral 
blood samples (80, 81). In contrast, the addition of IL-4 to 
IL-2-stimulated cell culture inhibits the development of CD4 
CTL in a dose-dependent manner. At sufficiently high antigen 
concentration, a low to intermediate level of cytotoxicity can be 
induced in the absence of IL-2, although this cytotoxic activity 
is primarily Fas/FasL mediated; exogenous IL-2 is required to 
induce perforin-mediated killing at all antigen concentrations 
(Figure 1). In vivo, it appears that the presence of inflammatory 
signals (such as pro-inflammatory cytokines or interferon signal-
ing) during infection can compensate for, or synergize with, low 
IL-2 levels, leading to the generation of cytotoxic CD4 effectors. 
Type I interferons such as IFN-α signal through STAT2; STAT2-
deficient mice exhibit significantly reduced GzmB expression 
in lung CD4 T cells following influenza infection, supporting 
the role of this pathway in generating CD4 CTL in  vivo. Loss 
of interferon regulatory factor 3 also impairs GzmB expression 
and CD4 memory cells (82), providing further evidence for the 
involvement of interferon signaling in CTL induction. Workman 
et al. have also suggested that inflammatory cytokines such as IL-6 
in the lung microenvironment may promote CD4 CTL activity, 
similar to the way in which CD8 CTL require signals from DCs 
and IL-15 during influenza infection (79). IL-15-responsiveness 
appears to be a trait shared by both CD4 and CD8 CTL; Mucida 
et al. showed that ThPOK− CD4 CTL in the murine gut remained 
quiescent when stimulated with only their cognate antigen, but 
exhibited cytotoxicity in the presence of antigen and IL-15 (69).
Modulation of antigen also impacts the functionality of CD4 
CTL. Low levels of antigen generate the highest levels of cyto-
toxicity and produce CTL that retain the ability to express IL-5, 
IL-10, and IL-13; in contrast, CTL generated with higher levels 
of peptide produce almost exclusively IFN-γ and TNF (78). In 
addition to antigen concentration, characteristics of the cognate 
peptide can significantly impact the generation of CD4 CTL both 
in vitro and in vivo (83). Carlier et al. demonstrated, for several 
well-described epitopes in transgenic mice, that insertion of a 
CxxC motif into the flanking residues of a major histocompat-
ibility complex (MHC) class II-restricted peptide results in 
acquisition of cytolytic activity by the antigen-specific CD4 T cell 
(Figure 1). This novel effector function is thought to occur due 
to an increased strength of the immunological synapse between 
the antigen-presenting cell (APC) and the antigen-specific CD4 
T cell (84), leading to lck/ZAP70-mediated signaling, promot-
ing T cell proliferation and expression of FasL and GzmB. Both 
naïve and polarized CD4 cells can acquire CTL activity through 
this mechanism, providing further evidence in agreement with 
Mucida et al. that T helper polarization is not a terminally dif-
ferentiated state.
Given the particular requirements for inflammatory signaling 
and antigen presentation in CD4 CTL generation, it is perhaps 
unsurprising that some tissues appear to better promote cytolytic 
activity than others. During acute influenza infection, protective 
CD4 effectors appear to be specifically generated at the site of 
infection in the lung, where inflammatory signals and antigen 
are highly concentrated (74). Importantly, multiple studies have 
shown the presence of in  vivo-generated GzmB+ CD4 CTL in 
the lung, but not the draining lymph nodes or spleen, at 7–8 days 
postinfection (64, 72). The microenvironment of the gut mucosa 
is similarly well suited to drive CD4 CTL differentiation, as the 
presence of local IFN-γ and IL-27 can promote T-bet expression 
(85). Unsurprisingly, delivery of antigen directly to mucosal tis-
sues therefore appears to be an efficient method of eliciting CD4 
CTL responses. Dutta et al. demonstrated that sterilizing immu-
nity to homotypic influenza virus can be induced in mice through 
intranasal, but not intramuscular, inoculation of low-dose PR8 
(86). In this model, intranasal infection was significantly more 
effective at inducing CD4 CTL activity in the lung than intra-
muscular infection, even at substantially lower infectious doses.
While these studies have provided substantial insight into the 
conditions under which CD4 CTL can be generated, the precise 
mechanisms associated with differentiation of CD4 CTL in vivo 
remain to be fully elucidated. New technology is now available 
to investigate single-cell transcriptomics, and future studies will 
likely identify transcription and repressor factors associated with 
typical CTL mRNAs such as for nkg7 (TIA-1), perforin, and 
granzymes at the single-cell level.
ANTiGeN ReCOGNiTiON BY CD4 CTL 
AND POSSiBLe TARGeTS
MHC Class ii-expressing APCs
Targets of CD4 CTL must express the MHC class II molecules. 
Cells that constitutively express HLA class II include APCs such 
as dendritic cells, macrophages including tissue-resident mac-
rophages such as Kupffer cells in the liver, alveolar macrophages in 
the lungs, and B cells. The question therefore arises as to whether 
CD4 CTL kill APCs during normal cognate antigen interaction. 
DC have been described as expressing SerpinB9, which is an 
inhibitor of GzmB (87), but whether this prevents cytotoxicity or 
is involved in cross-presentation to CD8 T cells is unknown (88). 
Nevertheless, CD4 CTL appear to be prominent in infections that 
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typically target APC or B cells, particularly those mediated by 
CMV, EBV, and dengue virus (DENV), and also HIV-1 that tar-
gets HLA class II+ activated CD4 T cells themselves, as discussed 
below. There are well-characterized pathways for viral-derived 
peptides to be presented by HLA class I on the surface of infected 
cells to CD8 CTL, but presentation by HLA class II on infected 
cells is less well characterized. HLA class II presentation by 
professional APC typically involves specialized endocytosis and 
transfer of peptides to HLA class II molecules in loading vesicles. 
One possible pathway for loading of viral peptides on HLA class 
II in infected cells may involve autophagy, and this presentation 
may be enhanced by IFN-γ (89).
Regardless of whether APC killing is a common function of 
CD4 CTL during natural viral infection, manipulation of cyto-
lytic CD4 responses may provide interesting new avenues for 
immunotherapy. Carlier et  al. raised CD4 CTL in vitro against 
peptides modified to contain a CxxC motif and demonstrated 
that these CTL are capable of inducing apoptosis in APCs, even 
if the APCs are presenting the original, non-CxxC-containing 
peptide. This approach allows for the suppression of both DC- 
and B cell-mediated immune responses; crucially, these CD4 CTL 
are also capable of killing bystander CD4 T cells that have come 
into contact with and are activated by the same APC, allowing an 
antigen-specific CD4 CTL to suppress polyclonal T cells recog-
nizing the same APC (84).
MHC Class i-expressing APCs
Surprisingly, cytolytic CD4 activity has been demonstrated to 
occur against myeloid APCs, in a MHC class I-dependent man-
ner (90). This function is specifically carried out by type 1 regula-
tory (Tr1) cells, which are CD4+ Foxp3− regulatory cells that are 
induced in the context of chronic antigen stimulation and IL-10 
production [recently reviewed in Ref. (91, 92)]. Recent identifica-
tion of the Tr1 surface phentoype as CD4+ CD49b+ LAG-3+ 
CD226+ has greatly facilitated research into their functions (93). 
Tr1 cells generated in vitro express GzmB and perforin and are 
capable of killing target cells with substantially greater efficiency 
than other cytotoxic CD4 cells (94), possibly due to high levels of 
STAT3 phosphorylation (95). Magnani et  al. demonstrated the 
perforin- and granzyme-mediated killing of myeloid APCs by Tr1 
cells, which was dependent not only on HLA class I recognition but 
also CD2 expression and recognition of myeloid APC CD155/112 
by Tr1-expressed CD226. As these cells are better defined, future 
studies will be able to provide a more comprehensive description 
of the role of cytotoxic Tr1 cells in suppressing and modulating 
the immune response during infection.
epithelial Cells and Other Non-APCs
Upregulation of MHC class II on murine lung epithelial cells, 
airway epithelial cells, or cell lines has been shown to occur 
following infection with Mycobacterium tuberculosis (96), 
influenza (72), and parainfluenza (97), respectively, as well as 
with IFN-γ treatment [reviewed in Ref. (13)], which is consistent 
with the ability of IFN-γ to upregulate MHC class II expression 
via JAK1/JAK2 activation (98). This upregulation occurs in 
both bone marrow-derived and non-bone marrow-derived cells 
(98). These observations highlight that infections with various 
pathogens lead to the upregulation of MHC class II expression on 
multiple cell types, allowing cells other than professional APCs 
to provide targets for CD4 CTL. During influenza infection, the 
trafficking and induction of CD4 CTL in the lung coincides with 
the expression of MHC class II molecules on lung epithelial cells 
at 5 days postinfection, which is likely critical for the contribution 
of CD4 CTL to protection from lethal infection (72). Similarly, 
hepatocytes are likely targets for CD4 CTL recognition during 
hepatitis infection, as these cells can express class II molecules 
and present antigen to virus-specific CD4 cells (99). A potential 
role for CD4 CTL activity in mediating immunopathology is sup-
ported by the observation that two patients who spontaneously 
cleared Hepatitis C virus (HCV) infection exhibited a significant 
decrease in perforin-expressing CD4 cells that coincided with 
viral RNA clearance.
virally induced Tumors As Targets
Several viral infections are associated with the development of 
malignancies, including human papillomavirus (100) and EBV 
(discussed later in this review). Tumors expressing viral antigens 
can therefore provide important targets for CD4 CTL activity. 
Cervical intraepithelial neoplasia, a premalignant abnormal 
growth preceding cervical cancer, is negatively associated 
with the presence of circulating cytotoxic CD4 T cells (101). 
Garcia-Chagollan et al. identified a population of CD4+ CD28± 
NKG2D+ T-cells, which appear to be overrepresented in cervical 
cancer patients and which express the cytotoxic markers CD107a 
and CD161 (102). While the role of CD4 CTL in protection 
against tumor formation requires more directed study, the use 
of immunotherapy and vaccination to induce cytotoxic CD4 
responses against tumor antigens is gaining interest, as discussed 
later in the review.
Tregs and Their Targets
Regulatory T cells, similar to Tr1 cells, play important roles in 
the suppression and regulation of the immune response. Tregs 
are defined by the expression of Foxp3 and can exert regulatory 
function through both cytokine production (notably IL-10 and 
TGFβ) and contact-dependent mechanisms including CTLA-4 
expression [reviewed by Arce-Sillas et al. (103)]. Nevertheless, the 
requirement for GzmB, but not perforin, in contact-mediated Treg 
suppression was clearly demonstrated in a mouse model (104) 
and further mouse studies demonstrated that GzmB expression 
in lung Tregs regulated cellular infiltration and inflammation 
during respiratory syncytial virus infection (105). The function 
and expression of granzyme and perforin in human Tregs, how-
ever, differs in some respects from the murine system. Efimova 
and Kelley reported that ex vivo, circulating human natural Tregs 
(nTregs) from healthy donors do not express GzmB and require 
both CD3/CD28 stimulation and IL-2 treatment to upregulate 
GzmB expression (106). GzmB induction was dependent on the 
mTOR and PI3K pathway. In direct contrast, however, Grossman 
et al. demonstrated that nTregs stimulated with anti-CD3/CD28 
and IL-2 upregulated the expression of GzmA, but not GzmB, 
and killed target cells via a perforin-dependent pathway (107). 
Currently, the reasons for this discrepancy are unknown and 
unresolved; in mice, GzmA, but not GzmB, contributes to Treg 
7Juno et al. Cytotoxic CD4 T Cells
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 19
function during graft-versus-host disease (108, 109), raising the 
possibility that human Tregs may selectively express GzmA and 
GzmB selectively under specific circumstances.
The induction of cytotoxicity by Tregs has several conse-
quences. First, Tregs must avoid self-inflicted apoptosis, as the 
expression of GzmB by nTregs has the potential to induce Treg 
death and prevent the suppression of target cells. In mice, Tregs 
concurrently upregulate both GzmB and the endogenous inhibi-
tor serine protease inhibitor 6, which hinders Treg apoptosis 
and promotes suppressive activity (110). Second, both Tregs and 
conventional CD4 CTL can exhibit cytotoxic responses against 
each other. When responder CD4 T cells and Treg are cocultured 
in the presence of IL-2, both cell populations can upregulate 
GzmA, GzmB, and perforin. At low concentrations of IL-2, Tregs 
became susceptible to responder cell cytotoxicity and were killed. 
At high concentrations of IL-2, however, the Tregs maintained 
their suppressive activity and induced apoptosis of the responder 
cells (111). A similar study, focused on an effector population of 
nTregs expressing HLA-DR, also demonstrated the capacity of 
responder CD4 cells to upregulate expression of GzmB after TCR 
stimulation and kill Tregs (112). Together, these studies dem-
onstrate the myriad of pathways through which CD4 cytolytic 
activity can play either a suppressive function or promote escape 
from regulatory responses.
iNFeCTiONS iN wHiCH CD4 CTL ARe 
PROTeCTive
Simian immunodeficiency virus
Antiviral CD4 CTL have been found in the response to simian 
immunodeficiency virus (SIV) infection of rhesus macaques. 
SIV-infected macaques controlling viral replication were 
depleted of CD8 T cells, leading to increased viremia that was 
rapidly controlled despite the lack of SIV-specific CD8 T cells 
(113). Viral control was associated with antibody responses 
and expansion of circulating SIV-specific CD4 T cells that were 
CD45RA− CD28+ CD95+ CCR7− and expressed GzmB (113). 
In a very similar study, Sacha et al. depleted CD8 T cells from 
elite controlling macaques and found robust Gag- and Nef-
specific CD4 T cell responses during the re-establishment of 
viral control (114). Interestingly, the SIV-specific CD4 T cells did 
not control viral replication in CD4 T cells ex vivo; however, they 
did recognize and eliminate SIV-infected macrophages (114). A 
recent comparison of monkey species in which SIV infection 
is either pathogenic or non-pathogenic found higher GzmB 
expression in CD4 T cells from pathogenic rhesus macaques 
(pathogenic infection) compared to African green monkeys 
(non-pathogenic infection) (115). Ayala et  al. very recently 
demonstrated cytolytic activity from an SIV Gag-specific CD4 
T cell clone that could control viral replication in other CD4 T 
cells as well as itself (116).
Human immunodeficiency virus
Activated CD4 T cells are the major targets of the HIV-1, and 
a proportion of HIV-specific CD4 T cells are infected and lost. 
Despite this, CD4 T cells with a cytotoxic profile are expanded in 
HIV-1-infected individuals. Compared to controls, Appay et al. 
showed that HIV-infected individuals exhibited higher numbers 
of CD4 T cells expressing perforin, GzmA, and GMP-17/TIA-1 
(9). Although these cells were detected early in infection, the 
highest numbers were found in individuals with chronic infec-
tion. The mechanism of cytotoxicity appeared to be primarily 
perforin mediated (9). Over the years, a number of groups have 
studied CD4 CTL during different stages of HIV-1 infection. 
During very early untreated primary HIV-1 infection (PHI; 
<22 days after the onset of symptoms), Zaunders et al. detected 
a 10- to 20-fold increase in the proportion of bulk CD4 T cells 
that were highly activated (CD38+++), proliferating (Ki-67+), 
and expressed the HIV-1 co-receptor CCR5 as well as GMP-17/
TIA-1, perforin, and GzmB (117). Within the same group of 
PHI individuals, Gag-specific IFN-γ+ CD4 T cells exhibited a 
similar CD38+++, Ki-67+, Bcl-2 low, CD57−, GMP-17/TIA-1+ 
phenotype (117). We recently confirmed in a second group of 
individuals with untreated PHI that CD4 T cells are consistently 
highly activated and express perforin, GMP-17/TIA-1, GzmB, 
and GzmK (15). Recently, Johnson et  al. characterized HIV-
specific CD107a+ CD4 T cells from individuals with PHI using 
Fluidigm analysis. They found that CD107a+ IFN-γ+ CD4 T 
cells shared a transcriptional profile with HIV-specific CD8 CTL, 
including expression of Gzms A, B, K, and perforin; importantly, 
the HIV-specific CD107a+ CD4 T cells exhibited similar killing 
activity to HIV-specific CD8 CTL (20).
Importantly, CD4 CTL emerge early during HIV-1 infection, 
correlate with acute viral load, and are associated with early viral 
load set point (20). Soghoian et  al. performed a longitudinal 
study of untreated individuals with early PHI and found that 
individuals who controlled viral replication within 12 months of 
infection had a significant expansion of HIV-specific CD4 T cells 
compared to individuals who progressed to higher viral set points 
(19). Viral controllers had higher expression of the degranula-
tion marker CD107a on Gag-specific CD4 T cells compared to 
non-controllers, and GzmA+ HIV-specific CD4 T cell responses 
at baseline were predictive of slower disease progression (19). 
Together, these studies clearly support a role for CD4 CTL in 
controlling early viral replication and contributing to delayed 
disease progression.
CD4 CTL may confer protection from disease progression 
through several mechanisms. First, p24 and Nef-specific CD4 
CTL can suppress HIV replication in both macrophages and T 
cells in vitro (10, 11, 118). In several cases, these CTL responses 
have been characterized in long-term non-progressors, who have 
been infected with HIV-1 but have remained asymptomatic for 
many years. In one such individual, Zaunders et al. identified a 
very large expansion of circulating CD4 T cells specific for p24, 
expressing CCR5 and the cytotoxic markers GMP-17/T1A-1, 
GzmA, and GzmB, that represented 5% of CD4 T cells in this 
individual (10). No cytotoxic activity was observed ex vivo; how-
ever, following a 10-day expansion with individual Gag peptides, 
purified CD4 T cells demonstrated peptide-specific cytotoxicity 
at even low effector to target ratios (10). Interestingly, these HIV-
specific CD4 T cells had originally been identified by their dra-
matic ability to proliferate in vitro in response to p24 (119–121). 
Second, CD4 CTL may provide immunological pressure on 
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HIV, similar to the well-documented impact of virus-specific 
CD8 CTL, which can lead to viral escape. Despite the apparent 
importance of CD4 CTL in the anti-HIV response, a conundrum 
for many researchers has been why viral escape from CD4 CTL 
pressure has not been widely identified. Considerable efforts have 
been made to demonstrate this phenomenon with very few cases 
noted in the literature. Harcourt et  al. described viral variants 
to p24 and p17 Gag epitopes in the proviral DNA of an HIV+ 
individual, the epitope variation did not diminish class II bind-
ing but were unable to stimulate proliferation of fresh PBMCs or 
cultured T cell lines (122). More recently, Burwitz et al. studied an 
elite controlling rhesus macaque that lost viral control and found 
that post-breakthrough sequencing identified a mutation in Gag 
p27 targeted by CD4 CTL, indicating the CD4 CTL were able to 
exert strong immune pressure in vivo (123).
influenza
As previously discussed, multiple groups have shown that CD4 
CTL are generated following acute influenza infection [recently 
reviewed in Ref. (27, 124)]. Influenza-specific CD4+ CTL were 
described as early as 1985 by Lukacher et al. (125), and further 
characterized a decade later when Graham et al. (75) demonstrated 
protective cytolytic activity in Th1, but not Th2, influenza-specific 
T cell clones in mice. The precise mechanisms by which CD4 T 
cells can provide protection against lethal or highly pathogenic 
influenza infection were identified in a transgenic mouse model 
of PR8 infection. In vitro primed CD4 effector cells adoptively 
transferred into naïve recipients provided protection in an IFN-
γ-independent manner by (A) promoting B cell maturation and 
antibody production and (B) perforin-mediated cytolytic activity 
(74). It was further shown that while antibody production was 
required in the later stages of infection to fully clear the virus, 
CD4 cytotoxicity was required earlier in infection to control 
viral replication. Cytolytic activity was Fas/FasL-independent 
and required the expression of perforin to provide protection, 
as demonstrated by perforin−/− effectors. Both Brown et al. (72) 
and McKinstry et al. (73) extended this work, demonstrating that 
CD4 effectors generated in vivo from the lungs of mice given a 
sublethal PR8 infection could similarly provide protection from 
lethal infection when transferred to naïve recipient mice. In 
these studies, CD4 perforin expression not only contributed to 
recovery and viral control following infection (72, 73) but exerted 
selective pressure leading to viral escape mutations (73). Those 
in  vivo-generated CD4 CTL can provide the same protection 
from infection as in vitro-generated cells provide evidence that 
the in vitro protocols use to induce CD4 cytotoxicity do approxi-
mate the mechanisms that lead to naturally occurring CD4 CTL 
clones.
Influenza-specific CD4 CTL have been identified in human 
subjects, even in the absence of strain-specific antibodies (26). 
Preexisting CD4 T cell responses were primarily directed 
toward the nucleoprotein and matrix protein, which tend to be 
conserved between strains, and expanded significantly follow-
ing subsequent viral challenge. Importantly, the frequency of 
baseline CD4 responses correlated inversely with illness sever-
ity following infection, while the expansion of these responses 
7 days post-challenge tracked with viral load and illness duration. 
Further characterization of baseline CD4 responses confirmed 
the ability of influenza-specific cells to perform perforin/
granzyme-mediate killing of B cell targets. Similar CD4 CTL 
responses are induced in humans following seasonal influenza 
vaccination (126). Although CD8 CTL vaccine responses are 
compromised in older adults compared to younger subjects by 
10 weeks postvaccination, CD4 cytolytic activity was comparable 
between all age groups, suggesting that the CD4 CTL response 
may be more durable in elderly persons. This is consistent with 
the observation that NKG2D+ CD4 T cells accumulate with age 
(58), potentially reflecting a preference for CD4 CTL responses in 
the elderly. Mouse models support this idea, as aged mice exhib-
ited delayed, but higher magnitude, CD4 CTL activity during 
influenza infection compared to younger mice (127). Additional 
studies specifically tracking CD4 CTL activity to various infec-
tions or vaccines in young and elderly adults will provide further 
insight into this observation.
Cytomegalovirus
Infection with human herpesvirus 5, otherwise known as 
CMV, leads to lifelong asymptomatic infection in healthy hosts. 
However, in the immunocompromised host such as transplant 
recipients or untreated HIV-infected individuals, CMV causes 
serious disease. CMV infects endothelial, epithelial, and glial cells 
in vivo, all of which express MHC class II molecules, particularly 
following induction by IFN-γ. During primary CMV infection in 
adults, CMV-specific CD4 T cells have been associated with better 
clinical outcome (128). These circulating CMV-specific CD4 T 
cells displayed an effector memory phenotype and produced the 
Th1 cytokines IFN-γ and TNF, as well as GzmB (59). Following 
cessation of viral load in primary CMV infection, a population of 
CD28−CD27− CD4 T cells expressing perforin and GzmB have 
been found to emerge and expand in the circulation of infected 
individuals (12).
During latent infection, Suni et al. found that CMV-specific 
CD4 T cells were CD4+CD8dim (8), and Appay et  al. showed 
that these cells were CD28−CD27−(9) and expressed perforin. 
Zaunders et  al. showed a high proportion of IFN-γ+ CMV-
specific CD4 T cells expressed GMP-17/TIA-1; furthermore, a 
subset of circulating CD4 T cells from CMV-seropositive adults 
expressed CCR5, GMP-17/TIA-1, GzmA, and CD244, with low 
expression of GzmB and perforin (10). Purified CD4+ CD8dim 
T cells possessed higher CMV-specific cytotoxicity compared 
to their CD4+ CD8− counterparts and were able to lyse whole 
CMV-loaded EBV-transformed B lymphoblastoid cells ex vivo 
(8). During this latent stage of infection, van Leewen et al. showed 
that CD4+ CD28− T cells emerged with immediate cytotoxic 
capacity, that these cells could lyse CMV antigen expressing 
target cells in a class II-dependent manner, and that CD28− CD4 
CTL clones common during latency were rare or absent during 
early infection (129). Casazza et al. hypothesized that CD4 T cells 
detected during chronic subclinical CMV infection expressed a 
specific effector phenotype. They revealed that CMV-specific 
CD4 T cells expressed IFN-γ, TNF, and MIP-1β in the absence 
of IL-2, had direct cytolytic activity (CD107a, perforin, GzmA, 
and B expression), and had a terminally differentiated phenotype 
(21). They suggested that the lack of IL-2 expression indicates that 
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these CD4 T cells are not present to provide “help” but more likely 
to have a direct antiviral effect.
Very recently, Pachnio et  al. confirmed that CMV-specific 
CD4 T cells possessed a highly differentiated effector memory 
phenotype and expressed IFN-γ, TNF, and MIP-1β. Using HLA 
class II tetramers to characterize CMV-specific CD4 T cells, 
they found that these cells had an “intense” cytotoxic profile; 
microarray analysis revealed an upregulation of genes associated 
with cytotoxic function, such as Gzms A, B, H, granulysin, and 
perforin, and that these cells also expressed CX3CR1 (a marker 
of endothelial homing) (130). CMV-specific CD4 CTL showed 
strong cytotoxic activity ex vivo against antigen-loaded targets 
(130). The same class II tetramer was used by Raeiszadeh et al. to 
demonstrate CMV-specific CD4 T cell reconstitution following 
stem cell transplantation; these cells had an effector memory 
phenotype and contained cytotoxic molecules (131). Shabir et al. 
followed an unselected group of kidney transplant recipients 
and examined the CD28− CD4 T cells. These cells were found 
predominantly in CMV-seropositive patients and expanded 
posttransplantation; they had an effector memory phenotype and 
expressed CX3CR1 as well as NKG2D and perforin (132).
Murine CMv (MCMv)
In MCMV, mice lacking CD4 T cells were shown to have an 
impaired ability to clear virus from the salivary glands, an 
important site of viral latency (133). Walton et al. revealed that the 
mechanism of CD4 T cell immune control in the salivary glands 
of MCMV infected mice was via direct secretion of IFN-γ, which 
induced antiviral signaling on non-hematopoietic cells (134). 
Adoptive transfer experiments of MCMV-specific effector CD4 
T cells to immune-compromised mice was found to be protec-
tive during pathogenic MCMV infection and IFN-γ was a vital 
mediator of this protective capacity (135). Despite the apparent 
importance of CD4 T cells in viral control in the above studies, 
there was no specific link to CD4 CTL. Verma et al. have recently 
utilized MHC II tetramers to phenotypically and functionally 
characterize the two first reported I-Ad-restricted CD4 T cell 
responses specific for MCMV. They show MCMV-specific CD4 
T cells in the liver express higher levels of GzmB than the same 
cells in the spleen. The organ-dependent expression of GzmB is 
reflected in in vivo CD4 CTL activity, with higher target cell loss 
in the liver compared to spleen. The data presented in this study 
suggest that MCMV-specific CD4 T cells can kill target cells in 
an epitope- and organ-specific manner. Additionally, they show 
that vaccination with CD4 T cell epitopes leads to reduced viral 
replication in tissues where CD4 CTL are observed (136).
Hantavirus
Haantan virus belongs to the Bunyaviridae family, and like other 
viruses in that family, can cause hemorrhagic fever with renal 
syndrome (HFRS). Screening of CD4 responses with peptide 
pools derived from the NTNV glycoprotein revealed a subset 
of virus-specific CD4 cells that expressed GzmB, perforin, and/
or CD107a (29). These cells were found at significantly higher 
frequencies and exhibited greater cytotoxicity among patients 
with mild/moderate disease compared to those with severe or 
critical illness. Furthermore, the frequency of GzmB+ CD4 cells 
correlated inversely with RNA load during acute HFRS, suggest-
ing a potential impact of CD4 CTL responses in the control of 
infection.
iNFeCTiONS THAT evADe CD4 CTL 
ReSPONSeS
epstein–Barr virus
Epstein–Barr virus is a ubiquitous herpesvirus that infects 95% 
of the human population by adulthood (137), taking the form 
of infectious mononucleosis in the acute phase. The high global 
prevalence of EBV infection results in EBV accounting for a 1% 
worldwide cancer incidence rate, with Hodgkin lymphoma, non-
Hodgkin lymphoma, nasopharyngeal carcinoma, and gastric 
cancers being the most common EBV-associated malignancies 
(138). The identification of cytotoxic EBV-specific CD4 responses 
dates back to 1984 (139), and similar responses have been identi-
fied in the mouse model of infection with γ-herpesvirus 68, in 
which cytolytic killing of virally infected cells by CD4 T cells has 
been observed in vivo (140, 141). Much of the work in this field 
has focused on identifying EBV epitopes from various stages of 
the lytic and latent phases of infection that may overcome viral 
immune evasion. Multiple studies have described CD4 CTL 
responses against latent-cycle antigens that evade recognition 
by CD8 CTL (142–144). The EBNA1 protein is expressed in all 
forms of EBV-related malignancy, making it an ideal candidate 
for immunotherapy; efforts to target a CD8 CTL response against 
the protein have been challenging, however, as a glycine-alanine 
repeat within the protein prevents presentation by MHC class 
I (145). Several groups have since shown that CD4 CTL can 
recognize EBNA1 epitopes and kill infected B cells (76, 142, 144). 
Interestingly, these CD4 CTL clones exhibited distinct phenotypic 
and functional characteristics compared to the influenza-specific 
CD4 CTL described previously; they exhibited a Th0 phenotype 
(with secretion of both IFN-γ and IL-4) and killed infected cells 
via Fas/FasL interactions rather than perforin secretion (144).
The relevance of these responses in  vivo and in immuno-
therapy approaches, however, is called into question with the 
observation that EBNA1-specific CD4 CTL identified in  vitro 
only poorly recognize native lymphoblastoid cell lines (LCLs) 
expressing EBNA1. Although this is commonly attributed to the 
protein’s limited access to the MHC class II presentation pathway 
(146), a recent study identifies EBV miRNA expression as a novel 
immune evasion mechanism (147). EBV-derived miRNAs sup-
press Th1 differentiation pathways, interfere with MHC class II 
antigen presentation, and subsequently inhibit the activation of 
EBV-specific CD4 CTL. Encouragingly, Long et al. (143) recently 
demonstrated that CD4 CTL responses to a variety of lytic cycle 
antigens could efficiently recognize EBV-transformed LCLs 
containing only a small proportion of lytically infected cells. This 
CD4 response was possible due to the uptake of lytic antigens by 
latently infected cells, which then efficiently processed and dis-
played epitopes for CD4 recognition. CD4 CTL also responded 
to a substantially broader array of lytic cycle proteins across the 
immediate early, early, and late phases compared to CD8 CTL, 
which skew toward immediate early proteins. Several other 
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studies have identified cytolytic CD4 responses to epitopes in the 
lytic protein BHRF1 (in HLA-DR*0401-positive subjects) (24), as 
well as BLLF1, BALF4, and BZLF1 (148). In vitro, T cell recogni-
tion of BLLF1/BALF4/BZLF1 epitopes did not require productive 
infection, could occur in the context of viral transfer to bystander 
B cells and was capable of controlling proliferation of infected 
B cells via cytolysis (148), further confirming the therapeutic 
potential of CD4 CTL (149).
Therapeutic induction of effector CD4 T cell responses 
against EBV antigen to fight malignancies demonstrate promise 
in animal models; effective killing of virus-induced tumor cells 
following treatment with a CD137 agonist was seen in CD8 T 
cell-deficient mice (150). In the same murine model, CD137 
signaling improved expression of pro-inflammatory cytokines 
and cytotoxic effector molecules in tumor-specific CD4 T cells, 
coincident with upregulation of Eomes and Tbox (151); these 
cells were able to kill virus-induced tumor cells in vivo. Moving 
in the preclinical direction of immunotherapy, EBNA1-specific 
CD4 T cells expressing effector cytokines and GzmB were 
induced following therapeutic EBV vaccination against rhEBNA1 
fused to the herpes simplex virus glycoprotein D, in rhesus 
macaques infected with lymphocryptovirus (152). Phase I human 
trials focus upon nasopharyngeal carcinoma, a malignancy 
more prevalent in South East Asia (153). Recombinant vaccinia 
virus encoding EBNA1 and LMP2 was applied intradermally to 
boost immunity in EBV-associated nasopharyngeal carcinoma 
patients. T-cell responses were detected postvaccination by IFN-γ 
ELISpot and mapped to MHC class II epitopes for both vaccine-
encoded proteins (154). Constructs specifically designed to target 
CD4 T cell response to EBV by encoding the CD4 T cell epitope 
enriched C-terminal EBNA1-fused to LMP2 (153), demonstrated 
functional differentiation and in vitro targeting of antigen-loaded 
cells, though epitope mapping was not performed. Efficacy 
studies thus demonstrate generation of CD4 CTL, which target 
antigen constitutively expressed in EBV-associated cancer, giving 
promise to development of Phase II trials and complementary 
therapies that lead to remission.
iNFeCTiONS iN wHiCH CD4 CTL MAY Be 
PATHOGeNiC
Dengue virus
The fact that DENV infection elicits cytotoxic CD4 T cell 
responses in humans has been known since 1989 (30), whether 
these cells are protective or pathogenic is currently unclear. 
Secondary infection with a dengue serotype different from the 
primary infection can lead to dengue hemorrhagic fever (DHF) 
and dengue shock syndrome (DSS). Multiple early studies 
demonstrated that DENV-specific CD4 CTL are cross-reactive 
against multiple serotypes (30–33), leading to the hypothesis that 
CD4 cytotoxicity may contribute to DHF and DSS. Additionally, 
Gagnon et al. (77) reported that capsid protein-specific CD4 CTL 
could mediate killing of both APCs (via perforin expression) and 
HepG2 liver cells (via Fas/FasL recognition). The authors con-
cluded that the killing of liver cells may also implicate CD4 CTL 
in the manifestation of liver disease that is frequently observed 
upon secondary infection. More recently, however, Weiskopf 
et  al. performed a more comprehensive characterization of ex 
vivo DENV-specific CD4 T cells and confirmed that these cells 
are strongly biased toward a cytolytic phenotype (155). Repeated 
dengue infection was associated with an expansion of DENV-
specific CCR7−CD45RA+ CD4 memory cells that expressed 
CD8α, CD107a, perforin, granzyme, Eomes, and CX3CR1 and 
were capable of killing target cells. In contrast to previous studies, 
Weiskopf suggested that CD4 CTL may play a role in reducing 
the severity of dengue infection due to the observation that the 
frequency of these cells is greater among individuals carrying 
the protective HLA-DRB1*04 allele. It is unclear whether any 
of the individuals with multiple dengue infections in this study 
experienced DHF/DSS; comparisons of CD4 CTL activity not 
only among individuals with or without protective HLA alleles 
but also among those with or without severe complications of 
secondary infection will be highly informative in the future.
viral Hepatitis
Relatively little is known about CD4 CTL responses in viral hepa-
titis. A comparison of individuals infected with Hepatitis B virus 
(HBV), HCV, and HBV/Hepatitis D virus (HDV) co-infection 
revealed a variable, but significantly increased, proportion of 
CD4 T cells expressing perforin ex vivo compared to healthy 
controls; in some individuals, up to 25% of bulk CD4 T cells 
were perforin+ (28). Perforin levels were significantly higher in 
HDV-infected subjects compared to HBV or HCV monoinfec-
tion and were, in fact, comparable to HIV-infected patients. As 
previously mentioned, the fact that liver hepatocytes may be a 
target of chronically induced CD4 CTL raises the issue of whether 
these cells contribute to immunopathology. Among all hepatitis 
patients, CD4 perforin expression correlated with aspartate ami-
notransferase levels and platelet counts and was highest among 
patients with the most advanced disease. Additional work, includ-
ing longitudinal studies, will be required to better define the role 
of CD4 CTL in viral hepatitis, as well as the antigen specificity of 
these CTL. While one study describes an HCV-specific TCR that 
can confer cytolytic activity when transduced into CD4 T cells 
(156), the in vivo CD4 CTL repertoire generated during chronic 
hepatitis infection remains to be described.
OTHeR viRAL iNFeCTiONS
Poxviruses—ectromelia and vaccinia 
viruses
CD4 CTL play an important role in the response to ectromelia 
virus, the pathogen responsible for mousepox. During acute 
ectromelia virus infection, a large number of CD4 T cells that 
express GzmB were found in the draining lymph nodes and liver 
of infected mice (157). These CD4 CTL demonstrated in  vivo 
MHC II-restricted CTL activity that was perforin dependent. 
Defective control of ectromelia virus was found in mice with 
a specific deficiency of perforin in their CD4 T cells (157). 
Comparisons of ectromelia virus and vaccinia virus (the active 
constituent of the smallpox vaccine) infection in mice showed 
that ectromelia virus induced significantly more CD4 CTL than 
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vaccinia with different epitope-specific CD4 cells exhibiting dif-
ferent cytotoxic frequencies (158). These results reveal that not 
all viral infections result in the generation of CD4 CTL with the 
same cytolytic ability.
The first descriptions of CD4 CTL in response to vaccinia virus 
in humans were from Littaua et al. and Demkowicz et al. (159, 
160) who established CD3+CD4+CD8−Leu11− cytotoxic T cell 
lines and clones from vaccinated individuals. These clones and 
cell lines were vaccinia virus-specific and lysed target cells in an 
HLA class II-restricted manner. The mechanism of lysis was not 
established for these CD4 cell lines or clones; however, further 
studies of vaccinia virus-specific cytotoxic CD4 T cell lines have 
shown that lysis was inhibited by concanamycin A, an inhibitor 
of perforin, but not by an anti-Fas antibody (161). Zaunders et al. 
(14) have shown that activated CD4 T cells detected in the early 
primary immune response to immunization with vaccinia virus 
expressed the cytotoxic granule marker TIA-1. The IFN-γ+ vac-
cinia virus-specific CD4 T cells detected in this study appeared 
as early as 11 days postvaccination and were shown to be pre-
dominantly TIA-1+ and were CD57−. A more recent study of the 
genetic profile of these activated CD4 T cells in the acute response 
to vaccinia virus has shown that these cells have a prominent 
CTL profile with upregulation of CTL associated genes including 
GzmK GzmA, KLRB1/CD161, Rab27a, and granulysin (15). The 
genes for perforin and TIA-1 were also upregulated; interestingly, 
the expression of GzmB was downregulated. From the same study, 
vaccinia virus-specific CD4 T cell lines were generated from a 
vaccinated individual at 13 days and 12 months postvaccination. 
These lines were shown to upregulate the machinery of cytotoxic 
degranulation and subsequently lyse HLA-matched target cells, 
loaded with autologous vaccinia virus peptides (15).
Parvovirus
Human parvovirus B19 is a relatively common viral infection; 
although it is often asymptomatic, infection has been associated 
with aggravation of rheumatoid arthritis and systemic lupus 
erythematosus (162). CD4 cells from B19 seropositive individu-
als exhibit perforin and GzmB expression following antigenic 
stimulation and are cytotoxic, albeit following a relatively long 
5-day stimulation (34). Interestingly, CD4 CTL in seropositive 
donors co-expressed IL-17 and CD56, two markers not previously 
associated with cytotoxic CD4 responses in other infections. The 
importance of these markers in CD4 CTL function and immunity 
to parvovirus B19 remains to be explored.
vACCiNe-iNDUCeD CD4 CTL
The mounting evidence that CD4 CTL are an important com-
ponent of protective immunity against many infectious diseases 
suggests that eliciting such cytotoxic responses may boost vaccine 
efficacy against infections such as HIV and influenza. Indeed, 
Watson et  al. (163) recently showed that the highly effective 
live-attenuated yellow fever vaccine elicits both CD8 and CD4 
CTL responses in a mouse model of infection. Both immune sera 
and CD4 T cells were required for full protection against fatal 
infection, which closely mimics the requirements described by 
Brown et  al. (74) for protection from fatal influenza infection 
and provides support for the goal of vaccine-elicited CD4 CTL 
responses.
Based on the evidence suggesting that the induction of Th1 
responses at the site of infection in the context of IL-2 and an 
inflammatory signal should induce an optimal CD4 CTL response 
against influenza infection, Vogel and Brown (164), tested the 
efficacy of intranasal immunization of inactivated influenza 
with CpG adjuvant. This vaccine induced high levels of inflam-
matory and chemotactic transcripts and significantly reduced 
viral burden in response to heterologous challenge. Compared 
to vaccination with inactivated influenza alone, the addition of 
CpG induced significantly higher GzmB expression in lung CD4 
T cells, which persisted after challenge with lethal PR8 infection. 
This approach may therefore be a good candidate for generating 
adaptive memory responses at the site of infection that are capable 
of limiting the replication of heterotypic viruses, particularly if 
well-conserved epitopes were chosen for vaccination. To that end, 
Babon et al. (165) identified a CD4 T cell epitope in the fusion 
peptide of the HA that is conserved across all influenza A HA 
subtypes as well as the influenza B HA protein. A CD4 T cell clone 
recognizing this epitope exhibits cytotoxicity to a variety of influ-
enza strains, including avian H5N1 virus. Importantly, the CD4 
clone is likely restricted by a common HLA allele, making this 
epitope an intriguing candidate for future vaccine studies. Using 
TLR-stimulating adjuvants to boost flu-specific CTL responses to 
conserved epitopes represents a novel avenue for future vaccine 
candidates (166).
The induction of CD4 CTL responses by an HIV vaccine may be 
similarly advantageous. Terahara et al. studied vaccine-induced 
SIV-specific CD4 T cell responses and found that CD107a+ 
vaccine-elicited CD4 T cells were more resistant to SIV infection 
than CD107a- cells, suggesting that CD4 CTL may be an ideal 
response to elicit during vaccination in order to avoid generating 
increased levels of target cells (167). While evidence does suggest 
the protective role of CD4 CTL induced early after infection, less 
work has focused on determining the efficacy of vaccine-induced 
CD4 CTL in humans. Vaccine-induced cell-mediated responses 
elicited by the modestly protective RV144 vaccine were assessed 
in HIV-uninfected individuals, and Env-specific polyfunctional 
effector memory CD4 T cells were detected along with high 
expression of CD107a in proliferating HIV-specific CD4 T cells 
(17). HIV-specific CD4 T cell lines grown from HIV-uninfected 
vaccinees were found to be polyfunctional and have cytolytic 
capacity in response to an Env peptide pool, suggesting that the 
vaccine did elicit some cytotoxic CD4 responses (17). Although 
not specifically linked to CD4 CTL, it is of interest to note that 
recent reanalysis of data from the original RV144 correlate analy-
sis (168) has shown that two vaccine-induced polyfunctional 
CD4 T cell subsets are associated with decreased risk of HIV 
infection (169). A more specific analysis of CD4 CTL activity in 
infected and uninfected vaccine recipients is warranted in future 
trials.
CONCLUSiON/FUTURe DiReCTiONS
Major histocompatibility complex class II-restricted CD4 T cells 
with a cytotoxic phenotype are a prominent component of the 
12
Juno et al. Cytotoxic CD4 T Cells
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 19
antiviral immune response. These CD4 CTL have been identified 
in response to a plethora of viral infections affecting mice, non-
human primates, and humans, and many aspects of their role in 
immunity remain unanswered. Despite the apparent importance 
of cytotoxic CD4 T cells in the immune response to many viruses, 
there is to date a paucity of reports in the literature of these cells 
placing any immune pressure on the virus as evidenced by CD4 
CTL escape. The lack of these data is intriguing and should be 
further studied to understand the immune pressure exerted by 
the antiviral CD4 CTL response. With regard to T regulatory 
cells, the role of granzymes in regulatory function needs to be 
confirmed, and differences between studies in humans and mice 
require clarification.
Future studies of CD4 CTL should concentrate on single-cell 
transcriptomics to further understand and define the CD4 CTL 
lineage. A large body of studies have been conducted on murine 
CD4 CTL; however, it is important to understand if such studies 
provide equivalent and translational information about human 
CD4 CTL. Further studies on how best to generate antigen-
specific CD4 CTL in vitro for cell therapy and immunization are 
also warranted.
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